HAE

As of 2026-09-10, HAE scores 60out of 100 on QNTM’s five-factor quantitative model, a high conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. HAE trades at $101.06, within its fair-value band.

HAE scores 60 out of 100 on QNTM's five-factor model — a high-conviction reading — 60 puts it among the strongest factor profiles the model tracks. Its strongest factor is value at 86 (exceptional), where it screens cheap on the model's valuation inputs, followed by momentum at 74. The weakest is volume at 41, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 9% of the Healthcare names the model scores.

On valuation, HAE is priced around the middle of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 62. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on HAE, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where HAE sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for HAE runs $81.96–$126.04. Current price $101.06 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.